SLC5A2 and metabolic dysfunction-associated steatotic liver disease: A systematic review of four RCTs and four observational studies done by Raj et al.44 reported favorable effects of SGLT-2 inhibitors on the level of liver enzymes, liver fat, and fibrosis in patients with NAFLD.